XML 50 R25.htm IDEA: XBRL DOCUMENT v3.20.1
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Agreement (Details)
3 Months Ended
May 18, 2020
USD ($)
$ / shares
shares
Apr. 30, 2020
USD ($)
subsidiary
$ / shares
shares
May 17, 2020
shares
Jan. 31, 2020
$ / shares
shares
Jan. 28, 2020
USD ($)
Merger Agreement          
Common stock, par value (in dollars per share) | $ / shares   $ 0.001   $ 0.001  
Conversion reverse stock split ratio 0.0833        
Common shares outstanding 1,367,326 1,523,185   1,268,991  
Number of rights outstanding   220,394      
Bridge Loan          
Merger Agreement          
Face amount of loan | $   $ 2,250,000     $ 2,250,000
Discount on notes payable | $   250,000      
Proceeds from loan | $   $ 1,250,000      
Bridge Loan | SUBSEQUENT EVENTS          
Merger Agreement          
Proceeds from loan | $ $ 1,000,000        
Merger Agreement          
Merger Agreement          
Common stock, par value (in dollars per share) | $ / shares $ 0.001        
Conversion reverse stock split ratio 0.0833        
Common shares outstanding 11,867,904        
Merger conversion ratio 629.57        
Number of preferred units     1,820,046    
Merger Agreement | Value Appreciation Rights          
Merger Agreement          
Number of rights outstanding 584        
Merger Agreement | Common Stock          
Merger Agreement          
Number of shares of common stock subject to rights (in shares) 367,670        
Merger Agreement | Series A convertible preferred stock          
Merger Agreement          
Shares issued upon completion of merger 1,821        
Merger Agreement | Timber Sub          
Merger Agreement          
Percentage of voting interests acquired 88.50%        
Merger Agreement | BioPharmX Corporation          
Merger Agreement          
Noncontrolling interest ownership percentage 11.50%        
BioPharmX          
Description of Business          
Number of wholly owned subsidiaries | subsidiary   1